Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04592445 · ClinicalTrials.gov registry record · NA

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

A NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Axon Therapies.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
20
Study locations

NCT04592445 is a NA study of Heart Failure With Preserved Ejection Fraction (HFPEF) that is actively recruiting participants, run by Axon Therapies. The registered enrollment target is 150 participants, below the 203-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04592445, a NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), is actively recruiting participants, sponsored by Axon Therapies.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

Conditions Studied

Heart Failure With Preserved Ejection Fraction (HFPEF)

Interventions

  • DEVICE Sham Control
  • DEVICE Greater Splanchnic Nerve Ablation

Study Locations (20)

New York

  • Weill Cornell Medicine - New York
  • Icahn School of Medicine at Mount Sinai - New York
  • Columbia University Medical Center - New York
  • Rochester General Hospital - Rochester

Illinois

  • Bluhm Cardiovascular Institute of Northwestern University - Chicago
  • University of Chicago Medical Center - Chicago
  • Prairie Education and Research Cooperative - Springfield

California

  • Scripps Health - La Jolla
  • University of California, San Francisco - San Francisco

Alabama

  • Cardiology PC - Birmingham

Arizona

  • Arizona Cardiovascular Research Center - Phoenix

Indiana

  • Ascension St. Vincent - Cardiovascular Research Institute - Indianapolis

Louisiana

  • Cardiovascular Institute of the South - Houma

Michigan

  • Michigan Medicine, University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2020-12-18
Est. Completion 2029-08-10
Phase NA

Sponsor

Axon Therapies

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04592445

The ClinicalTrials.gov registry entry for NCT04592445 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (26% lower). The listed sponsor is Axon Therapies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 2 interventions - of which Sham Control is the first listed.

NCT04592445 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Illinois, California.

Frequently Asked Questions

What is clinical trial NCT04592445 about?

NCT04592445 is a clinical study titled "Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF". The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether th...

What is the current status of trial NCT04592445?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2020-12-18. Estimated completion is 2029-08-10.

What conditions does trial NCT04592445 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF).

What interventions are being tested in trial NCT04592445?

The interventions under investigation include: Sham Control (DEVICE), Greater Splanchnic Nerve Ablation (DEVICE).

Who is sponsoring clinical trial NCT04592445?

This trial is sponsored by Axon Therapies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04592445 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction (HFPEF)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.